<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976169</url>
  </required_header>
  <id_info>
    <org_study_id>STU 042013-042</org_study_id>
    <nct_id>NCT01976169</nct_id>
  </id_info>
  <brief_title>Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)</brief_title>
  <official_title>Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard of care:

      Treatment with Trastuzumab

      Experimental:

      21-Day Cycle of Combination therapy with T-DM1 intravenously on Day 1 and oral PD-0332991 on
      Days 5-18

      Study Design and Methodology:

      This is a phase 1B inter-patient dose escalation study of PD-0332991 in combination with
      T-DM1 in patients with recurrent or metastatic HER2-positive breast cancer after prior
      trastuzumab or other HER2-directed therapies.

      The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes
      on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how
      well the subject tolerates the treatment.

      A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of
      PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18
      of each 21 day cycle.

      Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral)
      Cohort 3 : PD-0332991 - 200 mg daily (oral)

      The 3+3 design entails that if one patient out of the first three patients has a DLT, up to
      three additional patients will be entered at that dose level

      Treatment cycles will continue until disease progression or withdrawal from study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1B inter-patient dose escalation study of PD-0332991 in combination with
      T--DM1 in patients with recurrent or metastatic HER2-positive breast cancer after prior
      trastuzumab or other HER2-directed therapies. A standard 3+3 trial design will be used for
      PD-0332991 dose escalation cohorts. The 3+3 design entails that if one patient out of the
      first three patients has a dose-limiting toxicity (DLT), three additional patients will be
      entered at that dose level. The PD-0332991 dose levels will start at 100 mg po daily; the
      second cohort will receive 150mg po daily; the third cohort 200mg po daily. Patients receive
      PD-0332991 on days 5-18 of each 21 day cycle. T-DM1 will be given intravenously at 3.6 mg/kg
      on day 1 of each 21 day cycle.

      Toxicity will be assessed using the Common Terminology Criteria of Adverse Events (CTCAE)
      version 4.0 grading scale. Dose- limiting toxicity-DLT is defined as any drug-related grade 3
      non-hematologic toxicity or grade 4 hematologic toxicity lasting &gt;28 days after the last day
      of therapy. If two patients experience drug-related DLT, the maximal tolerated dose (MTD) for
      the combination in HER2-positive breast cancer patients has been exceeded, enrollment to that
      dose will stop, and the next lower dose will be designated the MTD. An additional 15 patients
      will be treated at the MTD or the maximal 200mg po daily PD-0332991 dose in combination with
      T-DM1 to confirm safety. Treatment cycles will continue until disease progression or
      withdrawal from study.

      Study End-points:

        1. To evaluate and assess Dose Limiting Toxicities (DLT).

        2. To determine the toxicity profile.

        3. To determine the clinical response rate.

        4. To determine the duration of response.

        5. To evaluate baseline HER2 positivity biomarkers by analyzing pretreatment tumor Ki67,
           phospho-RB, cleaved caspase 3, phospho-histone H3, cycline E, MCM7, HER2, p27Kip1.

        6. To evaluate post-treatment Ki67, phospho-RB, cleaved caspase 3, phospho-histone H3,
           cyclin E, MCM7, HER2, p27Kip1, Rb, p16ink4c, CDK4, CDK6 in order to establish biomarker
           response to treatment.

        7. To evaluate pharmacokinetic (PK) parameters for PD-0332991 and T-DM1 including Cmax,
           AUC, t1/2
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>42 days at the end of Cycle 2</time_frame>
    <description>A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.
Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>42 days at the end of Cycle 2</time_frame>
    <description>The 3+3 design entails that if one patient out of the first three patients has a DLT, up to three additional patients will be entered at that dose level</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PD-0332991 and T-DM1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.
A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.
Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-0332991 and T-DM1</intervention_name>
    <description>The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.
A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.
Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)</description>
    <arm_group_label>PD-0332991 and T-DM1</arm_group_label>
    <other_name>KADCYLA=T-DM1</other_name>
    <other_name>Palbociclib=PD-0332991</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.All subjects must be informed about the study and have signed a current IRB
             (Institutional Review Board) approved informed consent.

             2. All subjects must have recurrent or metastatic HER2-positive breast cancer.
             diagnosed by biopsy.

             3. All subjects must have previously received trastuzumab or other HER2 targeted
             therapies.

             4.Tumor must be HER2-positive and RB-proficient. RB (Retinoblastoma
             protein)-proficiency is determined by tumor biopsy demonstrating RB normal and p16in4a
             low by immunohistochemistry. RB proficiency means that there is an intact RB pathway
             indicative of responsiveness to PD-0332991. RB staining is scored on an absent (no
             nuclear staining), weak (nuclear staining less than observed in endothelial cells and
             stromal cells surrounding the tumor), positive (nuclear staining at or above
             surrounding tissue) (0, 0.5, 1 respectively). P16ink4a is a routine clinical stain
             that is scored using absent, weak, positive, strong (0,1,2,3 respectively). Tumors
             will be scored using [p16]/[RB], where a score of less than 3 is required for
             inclusion. RB loss is expected to occur in less than 15% of cases.

             5. Subjects must have a performance status of â‰¤ 2 on the ECOG (Eastern Cooperative
             Oncology Group)Performance scale.

             6. Subjects must have bilirubin &lt;1.5 mg/dl, transaminases &lt;2.5x upper limit of normal,
             albumin &gt;3gm/dl, creatinine &lt;1.3mg/dl, adequate cardiac reserve (EF&gt;50%), ANC
             (Absolute neutrophil count) &gt;1,000/mcL (microliter), and Platelets &gt;100,000/mcL.

             7. Must be willing to be treated at the University of Texas Southwestern Hospital,
             University of Pennsylvania and affiliated clinics.

             8. Subjects must be willing to use an approved form of birth control while on this
             study and for 90 days after completion.

             9. Age &gt; 18 years. 10. Subject must be able to swallow capsules and have no surgical
             or anatomic condition that will preclude the subject from swallowing and absorbing
             oral medications on an ongoing basis.

        Exclusion Criteria:

          -  1. Chemotherapy, radiotherapy or hormonal therapy within 3 weeks ( 6 weeks for
             nitrosoureas, mitomycin C or bevacizumab), or who have not recovered from the adverse
             events to &lt; grade 2 due to previous agents administered more than 4 weeks prior to
             Study Day 1.

             2. Subjects less than 4 weeks post major surgery. 3. Known active CNS metastases or
             carcinomatous meningitis. Subjects with CNS (Central Nervous System) metastases
             including brain metastases who have completed a course of radiotherapy are eligible
             for the study provided they are clinically stable. However, oral corticosteroids for
             control of CNS symptoms are not allowed.

             4. Known documented or suspected hypersensitivity to the components of the study
             drug(s) or analogs.

             5. Uncontrolled systemic illness, including but not limited to ongoing or active
             infection.

             6. Symptomatic congestive heart failure, unstable angina pectoris, stroke or
             myocardial infarction within 3 months.

             7. Baseline neuropathy &gt;grade 1. 8. Known positive for human immunodeficiency virus
             (HIV). Baseline HIV screening is not required.

             9. Pregnant or breast-feeding subjects. 10. Subjects who are unable or unwilling to
             abide by the study protocol or to cooperate fully with the investigator or designee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Haley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal Medicine Hematology Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Haley, MD</last_name>
      <phone>214-648-4180</phone>
      <email>barbara.haley@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gregg Wright</last_name>
      <phone>214-648-7097</phone>
      <email>James.Wright@UTSouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dawn Klemow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Knudsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Navid Sadeghi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lori Watumull, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Haley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2013</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Ado-trastuzumab emtansine</mesh_term>
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

